However, further studies are needed to explore tumor PD-L1 expression using different methods in melanoma patients (for example, employing artificial intelligence techniques to automatically analyze the immunohistochemical expression of PD-L1 in melanoma specimens), and additional comparative molecular analyses of primary tumors and metastases are required to gain a deeper understanding of the tissue-specific mechanisms that contribute to variations in therapy outcomes. This evidence concerns the gene CD274 and melanoma.